- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03273608
Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients
Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients: Safety & Efficacy Registry in Taiwan (SUPER- Taiwan)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence on deTACE in HCC management to physicians in the region, and to support the application of in treating advanced HCC patients.
Primary Objective:
To collect 1-year overall survival of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients in Taiwan.
Secondary Objectives:
- To evaluate the overall tumor response of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients. The tumor response is according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.
- To evaluate the local tumor response (in the tumor(s) treated with drug-eluting microsphere) by chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients.
- To evaluate the safety profile of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients.
Exploratory Objectives:
- To evaluate the downstaging and downsizing potential of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients to within Milan Criteria and to within Resection margin.
- To collect time-to-progression (TTP) and progress-free-survival (PFS) data of chemoembolization with drug-eluting microsphere in intermediate and advanced HCC patients.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Taipei, Taiwán, 11217
- Reclutamiento
- Taipei Veterans General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:Patients must meet all of the following inclusion criteria in order to be entered into the study:
- Age 20 or older.
- Patient has signed informed consent.
Patient must have a diagnosis of hepatocellular cancer confirmed by AASLD and at least one of the following method:
- Magnetic resonance imaging (MRI) with early enhancement and delayed enhancement washout of at least one solid liver lesion > 1 cm.
- Contrast enhanced computed tomography (CT) with early enhancement and delayed enhancement washout of at least one solid liver lesion > 1 cm.
- Histological confirmation is required for lesions with inconclusive features.
Patient must not be suitable for treatment by resection or percutaneous ablation at time of study entry.
- Patients not suitable for ablation due to lesion location may be enrolled.
- Patients with HCC recurrence but not suitable for resection or ablation maybe enrolled.
Patient MUST be with either BCLC stage B OR C, and meet the following criteria:
- Stage Child-Pugh A or B AND
- Performance status ECOG ≤ 1 WITH Vascular Invasion or WITHOUT Vascular invasion.
- Patient has a life expectancy of at least 6 months.
Exclusion Criteria:If patients meet any of the following criteria they may not be entered into the study:
- Current or previous treatment with chemo- or radiation therapy or sorafenib or drug-eluting chemoembolization (deTACE).
- Patients with concurrent cancer except non-melanomatous skin cancer.
- Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive.
- Performance status ECOG > 1.
- Child-Pugh Class C.
- Occlusive tumor thrombus to the main portal trunk.
- Active gastrointestinal bleeding.
- Evidence of uncorrectable bleeding diathesis.
- Extra-Hepatic spread of the HCC.
- Encephalopathy not adequately controlled medically.
- Presence of ascites not controlled medically.
- Any contraindication for MRI/ CT (eg. metallic implants).
- Allergy to contrast media that cannot be managed with prophylaxis.
- Any contraindication to arteriography.
- Any contraindication for doxorubicin administration.
- Any contraindication for hepatic embolization. Porto-systemic shunt, or an arteriovenous shunt that cannot be adequately closed prior to chemoembolization. Hepatofugal blood flow. Serum creatinine > 2mg/dL. Other condition deemed exclusionary by physician. Uncorrectable impaired clotting.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Solo caso
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall survival
Periodo de tiempo: 1 year
|
To define all participants from the day of the first HepaSphere Treatment until end of study or death is reported, whichever comes first.
|
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Tumor Response
Periodo de tiempo: 1 year
|
Tumor response will be assessed using modified Response Evaluation Criteria In Solid Tumors (mRECIST) criteria to evaluate tumor necrosis under CT/ MRI and will be presented as %.
|
1 year
|
Adverse Event (AE)
Periodo de tiempo: 1 year
|
Adverse event will be accessed according to CTCAE 4.0 after treatments until end of study or death.
|
1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Exploratory Objectives, Time-To-Progression (TTP)
Periodo de tiempo: 1 year
|
To define all participants from the day of the first HepaSphere Treatment until tumor progression or death is first reported, whichever comes first.
|
1 year
|
Exploratory Objectives, Downstaging
Periodo de tiempo: 1 year
|
Tumor staging will be accessed according to BCLC staging system and Milan criteria, and will be reviewed at follow-up until end of study or death.
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Yi-Hsiang Huang, M.D. Ph.D., Taipei Veterans General Hospital, Taiwan
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HEPA-Taiwan-001
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .